Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat
Medical Principles and Practice · 2024
DOI: 10.1159/000541488 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Medical Principles and Practice, 2024. Verfasst von Ali Ekin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Uludag University Faculty of Medicine, Bursa, Turkey. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Azetidines, Antirheumatic Agents, Sulfonamides. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
This study investigates the efficacy and safety of baricitinib, an oral targeted synthetic disease-modifying antirheumatic drugs (DMARDs), in patients with difficult-to-treat rheumatoid arthritis (D2T RA) compared to those without, aiming to determine its potential as an alternative treatment for D2T RA. Subject and Methods: A total of 78 patients participated in this retrospective cohort study, with 33 meeting the D2T RA criteria and 45 in the non-D2T RA group. Various clinical and laboratory parameters, adverse events, and disease activity indices were assessed, alongside drug efficacy and survival rates.
Results
Patients with D2T RA exhibited higher seronegativity, prior use of b-DMARDs and c-DMARDs, and longer disease duration. Both groups experienced reductions in VAS and DAS28 scores, as well as SDAI, CDAI, HAQ, CRP, and ESR levels at baseline and 3, 6, and 12 months post-baricitinib initiation, with sustained efficacy observed over 12 months. The most prevalent adverse event was infection (28.21%). Although initial drug survival rates were similar between groups, the non-D2T RA group demonstrated higher rates at 24 months (46.70% vs. 59.40%). Subgroup analyses showed comparable survival rates between D2T RA and non-D2T RA groups, whether treated with baricitinib alone or in combination with methotrexate or leflunomide.
Conclusion
Despite potential treatment resistance, patients meeting the D2T RA criteria shared similar safety and efficacy profiles with those non-D2T RA. Baricitinib emerges as a promising treatment option for D2T RA patients, offering effectiveness and safety comparable to the non-D2T RA group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Uludag University Faculty of Medicine, Bursa, Turkey.
- Department of Internal Medicine, Uludag University Faculty of Medicine, Bursa, Turkey.
Zitieren
APA
Ekin, A., Misirci, S., Görünen, A., Coskun, B. N., Yagiz, B., Dalkilic, E., & Pehlivan, Y. (2024). Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat. Medical Principles and Practice. https://doi.org/10.1159/000541488
Vancouver
Ekin A, Misirci S, Görünen A, Coskun BN, Yagiz B, Dalkilic E, et al. Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat. Medical Principles and Practice. 2024. doi:10.1159/000541488
BibTeX
@article{Ekin2024,
author = {Ekin, Ali and Misirci, Salim and Görünen, Ahmet and Coskun, Belkis Nihan and Yagiz, Burcu and Dalkilic, Ediz and Pehlivan, Yavuz},
title = {Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat},
journal = {Medical Principles and Practice},
year = {2024},
doi = {10.1159/000541488}
}
EUVIMED